Control Bionics Ltd. · ASX:CBL
Control Bionics — Investor Presentation (February 2026)
8 slides from Control Bionics's investor presentation, Feb 26, 2026
Slide 1: Business Update February 2026
For personal use only Business Update February 2026 Jeremy Steele
Slide 2: HY26 Financial Overview
HY26 Financial Overview HY26 Investor Update | February 2026 $2.8M $5.3M $3.1M For personal use only Revenue Capital Raised during the half, Closing cash balance Broadly consistent with the strengthening liquidity 31 December 2025 prior period, delivered with a leaner sales structure • Key strategic
Slide 3: NeuroNode Distributor Strategy
NeuroNode Distributor Strategy HY26 Investor Update | February 2026 Recent Progress • Two NN-only distribution agreements executed in the US • Tobii Dynavox: initial six-month pilot across five US states with confidence this will expand US- For personal use only wide • PRC-Saltillo: formal distribut
Slide 4: NeuroStrip Market Engagement
NeuroStrip Market Engagement HY26 Investor Update | February 2026 For personal use only NeuroStrip is in-market and Applications span healthcare, Engagement is being driven by being used across multiple performance, and institutional real-world use and outcomes settings environments
Slide 5: Next Level: Capital-Light Scale Opportunity
Next Level: Capital-Light Scale Opportunity HY26 Investor Update | February 2026 • Strategic partnership with NextLevel Assistive Technology to commercialise iOS-based speech- generating devices in the US For personal use only • Capital-light model, with NextLevel funding device tooling and manufact
Slide 6: Strategic Repositioning
Strategic Repositioning HY26 Investor Update | February 2026 • Strategic repositioning is nearing completion For personal use only • Focused on clearer articulation of priorities across NeuroNode, NeuroStrip, and platform opportunities • Intended to better reflect CBL’s evolving commercial model and
Slide 7: Disclaimer
Disclaimer HY26 Investor Update | February 2026 This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into
Slide 8: Contact Details
Contact Details HY26 Investor Update | February 2026 CEO and Managing Director For personal use only Jeremy Steele jsteele@controlbionics.com AUS: +61 433 229 470 US: +1 (855) 831-7521 www.controlbionics.com
Control Bionics — Investor Presentation (February 2026) on 6ix